NASDAQ · Biotechnology · USD
Clinuvel Pharmaceuticals Limited (CUVL) Stock Analysis
Clinuvel Pharmaceuticals Limited (CUVL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 22, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
CUVL Key Statistics
As of Oct 22, 2026Trading
- Open
- $5.15
- Previous Close
- $5.12
- Day's Range
- 4.95–5.40
- 52-Week Range
- 4.91–8.92
- Volume
- 22.99K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.58
Valuation
- Market Cap
- $253.95M
- P/E Ratio
- 11.18
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 2.70
- EPS (ttm)Profit attributable to each share over the last twelve months.
- 0.45
Financials (FY)
- Revenue (FY)
- $95.02M+7.76%
- Net Income (FY)
- $36.17M+1.50%
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 36.07%
- Shares Outstanding
- 50.49M
- 1-Year Return
- −33.38%
Dividend and dates
- Dividend
- $0.04+0.70%
- Ex-Dividend Date
- September 8, 2026
- Avg Volume
- 12.45K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 22, 2026, CUVL closed at $5.03, −33.38% over 1 year.
Clinuvel Pharmaceuticals Limited (CUVL) has a market capitalization of $253.95M.
In fiscal 2025, CUVL reported revenue of $95.02M.
CUVL Stock Return by Calendar Year
Clinuvel Pharmaceuticals Limited (CUVL) 10-year return: what $10,000 became
- 1 year
- $10,000 $6,662
- −33.38%
- 5 years
- $10,000 $1,733
- −82.67%
- 10 years
- $10,000 $9,608
- −3.92%
If you had invested $10,000 in Clinuvel Pharmaceuticals Limited (CUVL) 10 years ago, at the close on October 21, 2016, it would have been worth $9,608 at the close on October 22, 2026: −3.92% in total, −0.40% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −40.68% |
| 2025 | +10.13% |
| 2024 | −30.13% |
| 2023 | −24.75% |
| 2022 | −25.82% |
| 2021 | +17.96% |
| 2020 | −14.51% |
| 2019 | +53.48% |
| 2018 | +105.63% |
| 2017 | +18.71% |
| 2016 (partial year) | +34.60% |
As of October 22, 2026.
CUVL Revenue and Earnings by Fiscal Year
FY ends June| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $95.02M | $36.17M | 38.1% |
| 2024 | $88.18M | $35.64M | 40.4% |
| 2023 | $78.32M | $30.60M | 39.1% |
| 2022 | $65.72M | $20.88M | 31.8% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $95.02M | $79.14M | $45.73M | $36.17M | 38.1% |
| 2024 | $88.18M | $78.10M | $48.01M | $35.64M | 40.4% |
| 2023 | $78.32M | $69.53M | $44.10M | $30.60M | 39.1% |
| 2022 | $65.72M | $55.24M | $35.33M | $20.88M | 31.8% |
Annual figures as reported, in the company's reporting currency. As of June 30, 2025.
CUVL Dividend History
Dividends per share, 2024 · 1 payments
| Year | Dividends per share | Payments | Change |
|---|---|---|---|
| 2026* | $0.04 | 1 | — |
| 2024 | $0.03 | 1 | +6.3% |
| 2023 | $0.03 | 1 | +18.5% |
| 2022 | $0.03 | 1 | +50.0% |
| Year | Dividends per share | Payments | Change |
|---|---|---|---|
| 2026 (partial year) | $0.04 | 1 | — |
| 2024 | $0.03 | 1 | +6.3% |
| 2023 | $0.03 | 1 | +18.5% |
| 2022 | $0.03 | 1 | +50.0% |
| 2021 | $0.02 | 1 | +0.0% |
| 2020 | $0.02 | 1 | +5.9% |
| 2019 | $0.02 | 1 | +21.4% |
| 2018 | $0.01 | 1 | — |
Most recent payment: $0.04 per share, ex-dividend September 8, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.
CUVL Valuation vs Biotechnology Median
Median of 607 stocks| Metric | CUVL | Biotechnology median | vs median |
|---|---|---|---|
| P/E | 11.18 | 16.56 | 32% below |
| P/S ratio | 2.70 | 13.26 | 0.2x the median |
| Profit margin | 36.07% | −38.31% | 74.4 pts above |
Medians across 607 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 22, 2026.
Recent News
5 Reasons To Buy Clinuvel Pharmaceuticals After Its Nasdaq Uplisting
SeekingAlphaClinuvel Pharmaceuticals Limited (CUVL) Q4 2026 Earnings Call Transcript
SeekingAlphaCLINUVEL FY2026 Revenue Dips 1% To $94.0M From $95.0M, Cash Reserves Rise 12% To $252.1M Amid US Expansion Push
BenzingaClinuvel (NASDAQ:CUVL): A Quality Investing Screen Standout
ChartMill
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 22, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$135.64B
REGNRegeneron Pharmaceuticals, Inc.
$84.33B
MRNAModerna, Inc.
$80.90B
ARGXargenx SE
$55.07B
ONCBeOne Medicines AG
$43.49B
RVMDRevolution Medicines, Inc.
$40.23B
Popular Healthcare Stocks
Eli Lilly and Company
$1.17T
JNJJohnson & Johnson
$644.91B
ABBVAbbVie Inc.
$503.96B
UNHUnitedHealth Group Incorporated
$381.46B
MRKMerck & Co., Inc.
$363.27B